The reversal of clinical symptoms in CAPS patients upon treatment with recombinant IL-1 receptor antagonist (Anakinra) or with IL-1β blocking agents (e.g., Canakinumab, a neutralizing antibody) provided compelling ex adjuvantibus evidence for the key role of IL-1β (3). This evidence concerns the gene IL1B and cryopyrin-associated periodic syndrome.